# Refining fibroblast-to-cardiomyocyte transdifferentiation protocols to explore emergent self-organization in cardiac cultures

**Authors:** Elena Turchaninova, Sofya Robustova, Sandaara Kovalenko, Vitalii Dzhabrailov, Aleria Dolgodvorova, Serafima Romanova, Dmitriy Zybin, Mikhail Popov, Alsu Miftakhova, Sheida Frolova, Mikhail Slotvitsky, Alexander Romanov, Konstantin Agladze, Valeriya Tsvelaya

PMC · DOI: 10.1371/journal.pone.0343415 · PLOS One · 2026-03-23

## TL;DR

Researchers developed a simplified protocol to convert fibroblasts into cardiomyocytes, which could help restore heart function after injury.

## Contribution

A minimized four-component cocktail for efficient fibroblast-to-cardiomyocyte transdifferentiation is introduced.

## Key findings

- 56–83% of cells expressed α-actinin, indicating successful transdifferentiation.
- The protocol achieves functional efficiency sufficient to restore cardiac tissue conductivity.
- The cocktail's minimized formulation balances clinical applicability and functional efficiency.

## Abstract

Fibrotic scars post-myocardial infarction disrupt cardiac conduction, causing arrhythmias. We developed a minimized 4-component cocktail (CHIR99021/BMP4/Activin A/IWP2) for efficient fibroblast-to-cardiomyocyte transdifferentiation. The use of the developed four-component protocol enables the generation of cells with electrical excitability and key cardiomyocyte markers, as evidenced by 56–83% of cells expressing α-actinin. This level of partial reprogramming of fibroblast cells into cardiac cells is sufficient to restore cardiac tissue conductivity, with an efficiency that exceeds the critical percolation threshold. Systemic delivery of components is safe, but requires further optimization, which will open up opportunities for localized delivery through smart substrates and combinations with cell therapy. Minimization of the transdifferentiation cocktail is not a compromise, but a strategic advantage that provides an optimal balance between functional efficiency and clinical applicability, including safety, delivery, and manufacturing.

## Linked entities

- **Proteins:** actn1.L (actinin alpha 1 L homeolog)
- **Chemicals:** CHIR99021 (PubChem CID 9956119), BMP4 (PubChem CID 172638715), IWP2 (PubChem CID 2155128)
- **Diseases:** myocardial infarction (MONDO:0005068)

## Full-text entities

- **Genes:** Gata4 (GATA binding protein 4) [NCBI Gene 54254], Bmp4 (bone morphogenetic protein 4) [NCBI Gene 25296] {aka BOMPR4A}, Tbx5 (T-box transcription factor 5) [NCBI Gene 304514], Tgfb1 (transforming growth factor, beta 1) [NCBI Gene 21803] {aka TGF-beta1, TGFbeta1, Tgfb, Tgfb-1}, Cacnb2 (calcium voltage-gated channel auxiliary subunit beta 2) [NCBI Gene 116600] {aka Cacnlb2}, Sox2 (SRY-box transcription factor 2) [NCBI Gene 499593] {aka RGD1565646}, Ina (internexin neuronal intermediate filament protein, alpha) [NCBI Gene 24503] {aka Inexa, Intlaa, Nf66, alpha-Inx}, ACTN1 (actinin alpha 1) [NCBI Gene 87] {aka BDPLT15}, Ctnnb1 (catenin beta 1) [NCBI Gene 84353] {aka Catnb}, Inhba (inhibin subunit beta A) [NCBI Gene 29200], Bmp4 (bone morphogenetic protein 4) [NCBI Gene 12159] {aka Bmp-4, Bmp2b, Bmp2b-1, Bmp2b1}, Fgf2 (fibroblast growth factor 2) [NCBI Gene 54250] {aka Fgf-2, Fgf2a, bFGF}, TRIM31 (tripartite motif containing 31) [NCBI Gene 11074] {aka C6orf13, HCG1, HCGI, RNF}, Trim31 (tripartite motif-containing 31) [NCBI Gene 224762] {aka HCG1, HCGI, RNF}, BMP4 (bone morphogenetic protein 4) [NCBI Gene 652] {aka BMP2B, BMP2B1, MCOPS6, OFC11, ZYME}, Gja1 (gap junction protein, alpha 1) [NCBI Gene 24392] {aka Cx43, Cxnk1}, Fgf2 (fibroblast growth factor 2) [NCBI Gene 14173] {aka Fgf-2, Fgf2a, Fgfb, bFGF}, Tgfb1 (transforming growth factor, beta 1) [NCBI Gene 59086] {aka Tgfb}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, Mef2c (myocyte enhancer factor 2C) [NCBI Gene 499497] {aka RGD1563119}, Klf4 (KLF transcription factor 4) [NCBI Gene 114505] {aka GKLF}, Gamt (guanidinoacetate N-methyltransferase) [NCBI Gene 25257] {aka GMT}, Axin2 (axin 2) [NCBI Gene 29134] {aka axil, axin-2}
- **Diseases:** Stroke (MESH:D020521), Left anterior descending coronary artery (MESH:D000080038), ischemic (MESH:D002545), sudden cardiac death (MESH:D016757), Myocardial Infarction (MESH:D009203), spinal fracture (MESH:D016103), Heart Disease (MESH:D006331), CMM (MESH:D007319), death (MESH:D003643), fibrosis (MESH:D005355), Infarction (MESH:D007238), heart failure (MESH:D006333), HAF (MESH:D001734), Toxicity (MESH:D064420), CVDs (MESH:D002318), necrosis (MESH:D009336), iCMs (MESH:D002292), Fibrotic scars (MESH:D002921), tumorigenicity (MESH:D002471), IHD (MESH:D017202), REF (MESH:D011906), ischemia (MESH:D007511), arrhythmia (MESH:D001145), inflammation (MESH:D007249), hematological toxicity (MESH:D006402)
- **Chemicals:** streptomycin (MESH:D013307), EGTA (MESH:D004533), Y-27632 (MESH:C108830), Ca (MESH:D002118), CHIR99021 (MESH:C473711), Zoletil (MESH:C006131), Na+ (MESH:D012964), xylazine hydrochloride (MESH:D014991), NADH (MESH:D009243), Alexa Fluor 594 (-), tiletamine hydrochloride (MESH:D013992), tranylcypromine (MESH:D014191), isoflurane (MESH:D007530), 2-Mercaptoethanol (MESH:D008623), Di-8-ANEPPS (MESH:C089669), Triton-X100 (MESH:D017830), DMSO (MESH:D004121), penicillin (MESH:D010406), oxygen (MESH:D010100), PBS (MESH:D007854), KCl (MESH:D011189), SB431542 (MESH:C459179), SR (MESH:D013324), DAPI (MESH:C007293), MgCl2 (MESH:D015636), heparin (MESH:D006493), paraformaldehyde (MESH:C003043), alginate (MESH:D000464), Glutamax (MESH:C054122), RepSox (MESH:C550621), meloxicam (MESH:D000077239), Forskolin (MESH:D005576), MgATP (MESH:D000255), F-12 (MESH:C007782), KOH (MESH:C029943), HI (MESH:D006639), vitamin C (MESH:D001205), zolazepam hydrochloride (MESH:D015041), XAV939 (MESH:C544261), Water (MESH:D014867), CaCl2 (MESH:D002122), EDTA (MESH:D004492), K+ (MESH:D011188), insulin (MESH:D007328), D-glucose (MESH:D005947), essential amino acids (MESH:D000601), N2 (MESH:D009584), NaCl (MESH:D012965), HEPES (MESH:D006531), valproate (MESH:D014635), NaOH (MESH:D012972)
- **Species:** Rodentia (rodent, order) [taxon 9989], Mus musculus (house mouse, species) [taxon 10090], Rattus norvegicus (brown rat, species) [taxon 10116], Rattus (rat, genus) [taxon 10114], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** S410p
- **Cell lines:** Rat embryonic fibroblasts — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0594), HAF — Homo sapiens (Human), Finite cell line (CVCL_ZG36)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13008095/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13008095/full.md

## References

66 references — full list in the complete paper: https://tomesphere.com/paper/PMC13008095/full.md

---
Source: https://tomesphere.com/paper/PMC13008095